Jorge Rodriguez-Roda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jorge Rodriguez-Roda has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Edmundo Fajardo-Rodriguez
Hospital Universitario Ramón y Cajal
2 shared publications - José López Menéndez
Cardiac Surgery, Hospital Universitario Ramón y Cajal, Madrid, Spain
2 shared publications - Mercedes Castro-Pinto
Universidad de Alcalá, Dpto Biología de Sistemas/Fisiología, IRYCIS, 28871 Alcalá de Henares, Spain
2 shared publications - Rafael Muñoz Pérez
Hospital Universitario Ramón y Cajal
2 shared publications - Alessandro Parolari
Unit of Cardiac Surgery and Translational Research, IRCCS Policlinico S. Donato, University of Milan, Milan, Italy
1 shared publication - Amedeo Anselmi
Department of Thoracic and Cardiovascular Surgery, University Hospital Centre Rennes, Rennes, France
1 shared publication
Latest Publications
- 16 December 2021
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 61 (5) , 977-987
Five-year outcomes in trials comparing transcatheter aortic valve implantation versus surgical aortic valve replacement: a pooled meta-analysis of reconstructed time-to-event data
OBJECTIVES: The incidence of outcomes in trials comparing transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) is expected to be different in the short and long term. We planned a meta-analysis of reconstructed time-to-event data from trials comparing TAVI and SAVR to evaluate their time-varying effects on outcomes. METHODS: We performed a systematic review of the literature from January 2007 through September 2021 on Medline, Embase, the Cochrane Central Register of Controlled Trials and specialistic websites, including randomized trials with allocation to TAVI or SAVR that reported at least 1-year follow-up and that graphed Kaplan–Meier curves of end points. The comparisons were done with grouped frailty Cox models in a landmark framework and fully parametric models. RESULTS: Seven trials were included (7770 participants). TAVI showed a lower incidence of the composite of death or stroke in the first 6 months [risk-stratified hazard ratio (HR) 0.66, 95% confidence interval (CI) 0.56–0.77, P-value <0.001], with an HR reversal after 24 months favouring SAVR (risk-stratified HR 1.25; 95% CI 1.08–1.46; P-value 0.003). These outcomes were confirmed for all-cause death (risk-stratified HR after 24 months 1.18; 95% CI 1.03–1.35; P-value 0.01). TAVI was also associated with an increased incidence of rehospitalization after 6 months (risk-stratified HR 1.42; 95% CI 1.06–1.91; P-value 0.018) that got worse after 24 months (risk-stratified HR 1.67; 95% CI 1.24–2.24; P-value <0.001). CONCLUSIONS: Although it could appear that there is no difference between TAVI and SAVR in the 5-year cumulative results, TAVI shows a strong protective effect in the short term that runs out after 1 year. TAVI becomes a risk factor for all-cause mortality and the composite end point after 24 months and for rehospitalization after 6 months.
- 16 December 2021
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 61 (5) , 977-987
Five-year outcomes in trials comparing transcatheter aortic valve implantation versus surgical aortic valve replacement: a pooled meta-analysis of reconstructed time-to-event data
OBJECTIVES: The incidence of outcomes in trials comparing transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) is expected to be different in the short and long term. We planned a meta-analysis of reconstructed time-to-event data from trials comparing TAVI and SAVR to evaluate their time-varying effects on outcomes. METHODS: We performed a systematic review of the literature from January 2007 through September 2021 on Medline, Embase, the Cochrane Central Register of Controlled Trials and specialistic websites, including randomized trials with allocation to TAVI or SAVR that reported at least 1-year follow-up and that graphed Kaplan–Meier curves of end points. The comparisons were done with grouped frailty Cox models in a landmark framework and fully parametric models. RESULTS: Seven trials were included (7770 participants). TAVI showed a lower incidence of the composite of death or stroke in the first 6 months [risk-stratified hazard ratio (HR) 0.66, 95% confidence interval (CI) 0.56–0.77, P-value <0.001], with an HR reversal after 24 months favouring SAVR (risk-stratified HR 1.25; 95% CI 1.08–1.46; P-value 0.003). These outcomes were confirmed for all-cause death (risk-stratified HR after 24 months 1.18; 95% CI 1.03–1.35; P-value 0.01). TAVI was also associated with an increased incidence of rehospitalization after 6 months (risk-stratified HR 1.42; 95% CI 1.06–1.91; P-value 0.018) that got worse after 24 months (risk-stratified HR 1.67; 95% CI 1.24–2.24; P-value <0.001). CONCLUSIONS: Although it could appear that there is no difference between TAVI and SAVR in the 5-year cumulative results, TAVI shows a strong protective effect in the short term that runs out after 1 year. TAVI becomes a risk factor for all-cause mortality and the composite end point after 24 months and for rehospitalization after 6 months.
- Open Access
- 30 November 2021
- Published by Hospital Metropolitano in Metro Ciencia
- Vol. 29 ((suppl 2))
Manejo de la perforación tardía del miocardio secundaria al implante de un dispositivo electrónico intracardiaco
La perforación tardía de miocardio (PTMI) secundaria a un dispositivo electrónico intracardiaco (DEI), es una complicación poco frecuente pero que puede ser mortal.
- 30 November 2021
- Published by Hospital Metropolitano in Metro Ciencia
- Vol. 29 ((suppl 2))
Open AccessManejo de la perforación tardía del miocardio secundaria al implante de un dispositivo electrónico intracardiaco
La perforación tardía de miocardio (PTMI) secundaria a un dispositivo electrónico intracardiaco (DEI), es una complicación poco frecuente pero que puede ser mortal.
- Open Access
- 30 November 2021
- Published by Hospital Metropolitano in Metro Ciencia
- Vol. 29 ((suppl 2)) , 131-132
Uso de Duragraft frente a solución salina heparinizada en injertos de vena safena en cirugía de revascularización coronaria aislada, 12 meses de seguimiento: eventos cardiovasculares mayores
La cirugía de revascularización coronaria (CABG) es el tratamiento más efectivo en la cardiopatía isquémica, siendo la vena safena mayor el injerto más utilizado a nivel mundial. Objetivo. El objetivo principal de este trabajo fue evaluar en los grupos de Duragraft y solución salina heparinizada las incidencias de eventos cardiovasculares mayores (MACES) en una variable compuesta por (Muerte, infarto de miocardio (IM) y nueva revascularización) en un periodo de 12 meses posterior a la cirugía.
- 30 November 2021
- Published by Hospital Metropolitano in Metro Ciencia
- Vol. 29 ((suppl 2)) , 131-132
Open AccessUso de Duragraft frente a solución salina heparinizada en injertos de vena safena en cirugía de revascularización coronaria aislada, 12 meses de seguimiento: eventos cardiovasculares mayores
La cirugía de revascularización coronaria (CABG) es el tratamiento más efectivo en la cardiopatía isquémica, siendo la vena safena mayor el injerto más utilizado a nivel mundial. Objetivo. El objetivo principal de este trabajo fue evaluar en los grupos de Duragraft y solución salina heparinizada las incidencias de eventos cardiovasculares mayores (MACES) en una variable compuesta por (Muerte, infarto de miocardio (IM) y nueva revascularización) en un periodo de 12 meses posterior a la cirugía.